Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Volitionrx (VNRX) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Volitionrx (VNRX) over the last 4 years, with Q3 2025 value amounting to $108.2 million.

  • Volitionrx's Shares Outstanding (Diluted Average) rose 2312.89% to $108.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.2 million, marking a year-over-year increase of 2312.89%. This contributed to the annual value of $86.5 million for FY2024, which is 2147.36% up from last year.
  • As of Q3 2025, Volitionrx's Shares Outstanding (Diluted Average) stood at $108.2 million, which was up 2312.89% from $102.7 million recorded in Q2 2025.
  • Volitionrx's Shares Outstanding (Diluted Average)'s 5-year high stood at $108.2 million during Q3 2025, with a 5-year trough of $71.2 million in Q4 2023.
  • For the 3-year period, Volitionrx's Shares Outstanding (Diluted Average) averaged around $89.7 million, with its median value being $87.2 million (2024).
  • The largest annual percentage gain for Volitionrx's Shares Outstanding (Diluted Average) in the last 5 years was 2417.43% (2025), contrasted with its biggest fall of 1778.91% (2025).
  • Volitionrx's Shares Outstanding (Diluted Average) (Quarter) stood at $71.2 million in 2023, then rose by 21.47% to $86.5 million in 2024, then rose by 25.06% to $108.2 million in 2025.
  • Its last three reported values are $108.2 million in Q3 2025, $102.7 million for Q2 2025, and $96.5 million during Q1 2025.